Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 28, 2014; 20(36): 12892-12899
Published online Sep 28, 2014. doi: 10.3748/wjg.v20.i36.12892
Published online Sep 28, 2014. doi: 10.3748/wjg.v20.i36.12892
Multimodality treatment of potentially curative gastric cancer: Geographical variations and future prospects
Neil D Merrett, Discipline of Surgery, School of Medicine, University Of Western Sydney, Penrith, NSW 2751, Australia
Neil D Merrett, Department of Upper Gastrointestinal Surgery, Sydney South West Local Health District, Liverpool, NSW 2170, Australia
Author contributions: Merrett ND solely contributed to this manuscript.
Correspondence to: Neil D Merrett, Professor, Discipline of Surgery, School of Medicine, University Of Western Sydney, Locked Bag 1797, Penrith, NSW 2751, Australia. n.merrett@uws.edu.au
Telephone: +61-2-46203736 Fax: +61-2-46203890
Received: November 3, 2013
Revised: January 2, 2014
Accepted: April 2, 2014
Published online: September 28, 2014
Processing time: 332 Days and 3.5 Hours
Revised: January 2, 2014
Accepted: April 2, 2014
Published online: September 28, 2014
Processing time: 332 Days and 3.5 Hours
Core Tip
Core tip: Multimodality therapy targeting occult micrometastatic disease is now accepted as the standard of care in the curative treatment of gastric cancer. Debate remains as to the best therapeutic regime and there is significant regional variation in the treatments which are routinely used. This review explores the evolution of multimodality treatments and perspectives for future developments including personalization of therapy.